Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin

MLA

Susanne Paukner, et al. “Pooled Microbiological Findings and Efficacy Outcomes by Pathogen in Adults with Community-Acquired Bacterial Pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Trials of Lefamulin versus Moxifloxacin.” Journal of Global Antimicrobial Resistance, vol. 29, no. 434–443, June 2022, pp. 434–43. EBSCOhost, https://doi.org/10.1016/j.jgar.2021.10.021.

APA

Susanne Paukner, Lisa Goldberg, Elizabeth Alexander, Anita F. Das, Stefanie Heinrich, Pritty Patel, Gregory J. Moran, Christian Sandrock, Thomas M. File, J., Jorge E. Vidal, Ken B. Waites, Steven P. Gelone, & Jennifer Schranz. (2022). Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin. Journal of Global Antimicrobial Resistance, 29(434–443), 434–443. https://doi.org/10.1016/j.jgar.2021.10.021

Chicago

Susanne Paukner, Lisa Goldberg, Elizabeth Alexander, Anita F. Das, Stefanie Heinrich, Pritty Patel, Gregory J. Moran, et al. 2022. “Pooled Microbiological Findings and Efficacy Outcomes by Pathogen in Adults with Community-Acquired Bacterial Pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Trials of Lefamulin versus Moxifloxacin.” Journal of Global Antimicrobial Resistance 29 (434–443): 434–43. doi:10.1016/j.jgar.2021.10.021.